Bufexamac – 25 mg

Brand:
Cayman
CAS:
2438-72-4
Storage:
4
UN-No:
Non-Hazardous - /

Bufexamac is an NSAID and inhibitor of the class IIb histone deacetylases HDAC6 and HDAC10.{43497} It inhibits the production of IFN-α in peripheral blood mononuclear cells (PBMCs; EC50 = 8.9 µM). Bufexamac induces hyperacetylation of tubulin (IC50 = 2.9 µM), a major substrate of HDAC6, without increasing acetylation of the class I HDAC substrates H3K5 or H3K9/K14. It also inhibits leukotriene A4 (LTA4) hydrolase and aminopeptidase activity (IC50s = 15.86 and 11.59 µM, respectively) and 5-lipoxygenase (5-LO) activity (IC50 = 27 µM).{43498,43499} Bufexamac inhibits the production of leukotriene B4 (LTB4; Item No. 20110) in neutrophils (IC50 = 12.91 µM) and reduces fMLP-induced neutrophil migration when used at concentrations of 50 and 100 µM.{43498} It also reduces neutrophil levels, as well as protein levels of TNF-α and IL-1β, in bronchoalveolar lavage fluid (BALF) in a mouse model of LPS-induced acute lung injury when administered at a dose of 100 mg/kg.  

 

Available on backorder

SKU: 26068 - 25 mg Category:

Description

An NSAID and a class IIb HDAC inhibitor; inhibits IFN-α production in PBMCs (EC50 = 8.9 µM); induces hyperacetylation of tubulin (IC50 = 2.9 µM); inhibits LTA4 hydrolase and aminopeptidase activity (IC50s = 15.86 and 11.59 µM, respectively); inhibits 5-LO (IC50 = 27 µM); inhibits the production of LTB4 in neutrophils (IC50 = 12.91 µM) and reduces fMLP-induced neutrophil migration at 50 and 100 µM; reduces neutrophil levels, as well as TNF-α and IL-1β protein levels, in BALF in a mouse model of LPS-induced acute lung injury at 100 mg/kg


Formal name: 4-butoxy-N-hydroxy-benzeneacetamide

Synonyms: 

Molecular weight: 223.3

CAS: 2438-72-4

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Deacetylases||Product Type|Biochemicals|Small Molecule Inhibitors|Peptidases & Proteases||Research Area|Epigenetics, Transcription, & Translation|Erasers|Histone Deacetylation||Research Area|Immunology & Inflammation|Inflammatory Lipid Mediators|Leukotrienes||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Lipid Biochemistry|Lipoxygenase Pathways